Abstract
Neoantigens arising from tumor-specific genomic alterations constitute authentic non-self antigens and represent a new class of targets for cancer immunotherapy. Recent reports on various vaccine platforms targeting neoantigens suggest a basis for precision therapies customized to each patient's tumor mutational profile.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Animals
-
Antigens, Neoplasm* / immunology
-
Antigens, Neoplasm* / therapeutic use
-
Cancer Vaccines* / immunology
-
Cancer Vaccines* / therapeutic use
-
Humans
-
Immunogenicity, Vaccine*
-
Immunotherapy*
-
Neoplasms* / immunology
-
Neoplasms* / pathology
-
Neoplasms* / therapy
Substances
-
Antigens, Neoplasm
-
Cancer Vaccines